Thymosin Beta-10

Thymosin beta-10 binds G-actin monomers with high affinity in a 1:1 complex, preventing their polymerization into F-actin filaments. The ABS (actin-binding sequence) of Tb10 shares ~75% homology with Tb4 at the critical binding residues. By maintaining a large pool of unpolymerized actin, Tb10 modulates the balance between protrusive lamellipodia (promoting migration) and stable stress fibers (limiting migration). In cancer cells, altered Tb10:Tb4 ratios shift this balance to favor enhanced motility and invasive phenotypes.

Elevated Tb10 in cancer correlates with increased matrix metalloproteinase (MMP) production, integrin signaling, and invadopodia formation, all processes requiring dynamic actin remodeling. Tb10 knockdown in thyroid and ovarian cancer cell lines reduces migration, invasion, and anchorage-independent growth in vitro. In animal models, Tb10-overexpressing cancer cells show enhanced metastasis. The mechanism links Tb10-mediated G-actin availability to WASP/Arp2/3-driven actin polymerization at invasion fronts.

Tb10 was initially identified as a gene induced by nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in PC12 pheochromocytoma cells. During neuronal differentiation, Tb10 expression rises as neurons extend neurites, processes dependent on dynamic actin remodeling. Tb10 is expressed in developing brain and peripheral nervous system, suggesting developmental actin regulatory functions shared with but distinct from Tb4.

Tb10 mRNA and protein are consistently elevated in multiple cancer types including papillary thyroid carcinoma (2-10x normal), ovarian cancer, colorectal cancer, and gastric cancer versus adjacent normal tissue. In thyroid cancer, elevated Tb10 correlates with lymph node metastasis and extrathyroidal extension. These correlations suggest Tb10 as a diagnostic biomarker in tissue biopsy or potentially in liquid biopsy platforms as a cancer-associated peptide.

siRNA-mediated knockdown of Tb10 in thyroid and ovarian cancer lines reduces proliferation, migration, invasion, and anchorage-independent colony formation. Tb10 knockdown also sensitizes cancer cells to chemotherapy (paclitaxel, cisplatin) in some cell lines, suggesting that Tb10-mediated actin dynamics confer chemoresistance. These data establish Tb10 as a potential oncology target, though no Tb10-specific inhibitors have reached clinical development.

In neuronal development models, Tb10 induction downstream of TrkA (NGF receptor) and TrkB (BDNF receptor) regulates neurite outgrowth and growth cone dynamics. Inhibiting Tb10 induction reduces NGF-driven differentiation in PC12 cells. This places Tb10 in the neurotrophin signaling cascade relevant to neuronal plasticity, nerve regeneration research, and potentially neurodegeneration, though therapeutic applications remain far from clinical development.